AIIA, Nisarga Herbs start trials of Ayurvedic Covid-19 prevention medicine - Hindustan Times
close_game
close_game

AIIA, Nisarga Herbs start trials of Ayurvedic Covid-19 prevention medicine

Hindustan Times, New Delhi | Byhindustantimes.com | Edited by: Shankhyaneel Sarkar
Aug 21, 2020 09:41 AM IST

The tests began on August 7 on 250 individuals. The tests are being conducted using the double-blind trial method where half of the individuals will receive proprietary Neem capsules while the other half will be administered for 28 days.

All India Institute of Ayurveda in collaboration with Nisarga Biotech Pvt Ltd will start human trials to check the preventative effect of neem capsules in people who have come in contact with Covid-19 patients.

Neem’s anti-inflammatory, anti-viral, and antioxidant properties could be beneficial in preventing Covid-19.(Sanchit Khanna/HT PHOTO)
Neem’s anti-inflammatory, anti-viral, and antioxidant properties could be beneficial in preventing Covid-19.(Sanchit Khanna/HT PHOTO)

The trials will be conducted in ESIC Medical College and Hospital, Faridabad led by Prof. (Dr.) Tanuja Nesari, MD, PhD, Director of AIIA and Dr. Asim Sen, Dean ESIC medical college will lead the team of six doctors from AIIA and ESIC.

Hindustan Times - your fastest source for breaking news! Read now.

The tests began on August 7 on 250 individuals. The tests are being conducted using the double-blind trial method where half of the individuals will receive proprietary Neem capsules while the other half will be administered for 28 days. In a double-blind trial, the doctors as well the participants in the trial do not know if they are taking the medicine for which the trial is being conducted or they are taking a blank capsule. This is done to eliminate bias towards the drug whose efficacy is being tested.

Girish Soman, Founder and CEO of Nisarga Biotech Pvt Ltd said, “We are excited to launch this study led by Dr. Prof. Tanuja Nesari, MD, PhD, Director, Head and Professor at AIIA, New Delhi. Dr. Nesari has extensive experience in Ayurvedic and modern research and her experience will help in evaluation of proprietary Neem formulation for prevention of Covid-19.”

Dr. Mohini Barde who is the medical director of this trial highlighted that the primary reason Neem was selected was due to its anti-inflammatory, anti-viral, and antioxidant properties. She also pointed out that Neem’s ability to bind with virus which has been outlined in molecular docking studies is also a reason for selecting Neem.

Dr Barde said, “This trial may lead to an affordable treatment option now that we are talking of learning to live with Covid 19.”

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! -Login Now!
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, February 27, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On